Institute of Pharmacy and Pharmacology, The First People's Hospital of Chenzhou, Hengyang Medical School, University of South China, Chenzhou, 423000, Hunan, People's Republic of China.
Department of Thoracic Surgery, The Third Hospital of Changsha, Changsha, 410035, People's Republic of China.
J Transl Med. 2022 Aug 2;20(1):349. doi: 10.1186/s12967-022-03553-x.
Lung cancer is the second cancer and the leading cause of tumor-related mortality worldwide. Angiogenesis is a crucial hallmark of cancer development and a promising target in lung cancer. However, the anti-angiogenic drugs currently used in the clinic do not achieve long-term efficacy and are accompanied by severe adverse reactions. Therefore, the development of novel anti-angiogenic therapeutic approaches for lung cancer is urgently needed. Non-coding RNAs (ncRNAs) participate in multiple biological processes in cancers, including tumor angiogenesis. Many studies have demonstrated that ncRNAs play crucial roles in tumor angiogenesis. This review discusses the regulatory functions of different ncRNAs in lung cancer angiogenesis, focusing on the downstream targets and signaling pathways regulated by these ncRNAs. Additionally, given the recent trend towards utilizing ncRNAs as cancer therapeutics, we also discuss the tremendous potential applications of ncRNAs as biomarkers or novel anti-angiogenic tools in lung cancer.
肺癌是全球第二大癌症和肿瘤相关死亡的主要原因。血管生成是癌症发展的关键标志，也是肺癌治疗的一个有前途的靶点。然而，目前临床上使用的抗血管生成药物并不能达到长期疗效，而且伴随着严重的不良反应。因此，迫切需要开发用于肺癌的新型抗血管生成治疗方法。非编码 RNA（ncRNA）参与癌症中的多种生物学过程，包括肿瘤血管生成。许多研究表明，ncRNA 在肿瘤血管生成中发挥着重要作用。本综述讨论了不同 ncRNA 在肺癌血管生成中的调控作用，重点讨论了这些 ncRNA 调控的下游靶标和信号通路。此外，鉴于最近将 ncRNA 用作癌症治疗的趋势，我们还讨论了 ncRNA 作为肺癌生物标志物或新型抗血管生成工具的巨大潜在应用。
